24小时热门版块排行榜

>论坛更新日志 (3592)
>虫友互识 (809)
>论文投稿 (263)
>休闲灌水 (216)
>导师招生 (162)
>基金申请 (144)
>文献求助 (129)
>硕博家园 (95)
>考博 (78)
>公派出国 (71)
>博后之家 (67)
>教师之家 (61)
>考研 (51)
>论文道贺祈福 (41)
>招聘信息布告栏 (38)
>找工作 (33)

返回列表

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

mollyzhang

铁杆木虫 (著名写手)

应助: 13 (小学生)
金币: 10247.1
散金: 350
红花: 4
帖子: 2490
在线: 417.4小时
虫号: 53071
注册: 2004-09-12
性别: GG
专业: 药物化学

[交流] FDA批准强生Canagliflozin用于2型糖尿病已有7人参与

2013年1月11日讯 /生物谷BIOON/ --强生旗下的杨森制药公司10日宣布，其糖尿病药物canagliflozin（商品名 INVOKANA™）获得FDA专家委员会10：5投票推荐批准，用于治疗成人2型糖尿病。

Canagliflozin是一种SGLT2抑制剂药物，能通过将葡萄糖分解后通过肾脏排出体外的方式来降低血糖，具有广阔前景。（生物谷Bioon.com）

20130111101812190.png

FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes
RARITAN, NJ, January 10, 2013 – Janssen Research & Development, LLC (Janssen) announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 – 5 to recommend approval for canagliflozin, proposed trade name INVOKANA™, to treat type 2 diabetes in adult patients based on the efficacy and safety results from its comprehensive clinical development program.

Canagliflozin is an investigational, oral, once-daily medication for the treatment of adult patients with type 2 diabetes. If approved by the FDA later this year, it would be the first in this new class of diabetes therapies available in the U.S. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people who do not have diabetes, which may contribute to elevated glucose levels. Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in people with diabetes who have elevated blood glucose levels.

“We are pleased with the positive recommendation from the committee and look forward to working with the FDA to bring this important new therapy to patients in the U.S. to help them manage their type 2 diabetes,” said Peter Stein, M.D., Head, Metabolism Development, Diabetes Disease Area Leader, Janssen. "Today’s outcome represents an important step toward achieving that goal."

Data presented at today’s advisory committee meeting included results from the comprehensive global Phase 3 clinical program, which enrolled 10,285 patients in nine studies; it is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. Canagliflozin was evaluated at 100 mg and 300 mg once-daily doses in placebo- and active comparator-controlled studies, as well as three large studies in special populations: older patients, patients with moderate renal impairment, and patients who had or were at risk for cardiovascular disease. Results showed that in addition to the improvements in glycemic control, both doses of canagliflozin were associated with weight loss and reductions in blood pressure across clinical studies.

Canagliflozin was generally well tolerated. It has specific safety and tolerability issues that were well characterized in this development program (such as the genital mycotic infections, urinary tract infections) and can be well managed by the physician and by the patient for some of these issues.

Janssen presented data from Phase 3 studies at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) in Barcelona in November.

The FDA will consider the advisory committee recommendation in its review of the New Drug Application (NDA) for canagliflozin that was submitted by Janssen on May 31, 2012, though the FDA is not bound to follow it.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. and its affiliates have marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand, and parts of Asia.

[ Last edited by mollyzhang on 2013-1-12 at 12:52 ]

回复此楼